Floatz logo

Toripalimab

Urological Cancer

Shanghai Junshi Bioscience Co., Ltd.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Urological Cancer cohort.

Asset / SponsorPhaseRating
Tadalafil
Regina Elena Cancer Institute
Phase 3B
Nivolumab
Spanish Oncology Genito-Urinary Group
Phase 2B
Ipilimumab
Dana-Farber Cancer Institute
Phase 2B
Atezolizumab
British Columbia Cancer Agency
Phase 2B
AMCASERTIB
Sumitomo Pharma America, Inc.
Phase 2CCC

View all 31 →

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →